Supporting Information for

Biomimetic Virus-like Particles as SARS-CoV-2 Positive Controls for RT-PCR Diagnostics

Soo Khim Chan¹, Pinyi Du², Karole Ignacio², Sanjay Metha², Isabelle Newton³, Nicole F. Steinmetz^{1,3,4,5,6,7*}

¹Department of NanoEngineering, ²Department of Medicine, ³Department of Radiology ⁴Department of Bioengineering, ⁵Center for Nano-ImmunoEngineering, ⁶Moores Cancer Center, ⁷Institute for Materials Discovery and Design, University of California San Diego, 9500 Gilman Dr., La Jolla CA 92039, USA.

*correspondence: <u>nsteinmetz@ucsd.edu</u>

| 5'- TAA TAC G | AC TCA CTA TA | AG GG AAATGO | <u>C A TGTC TAA G</u> | AC AGC AT CTT | C AAAATGTCTG | ATAATGGACC |
|---------------|---------------|--------------|-----------------------|---------------|--------------|----------------|
| CCAAAATCAG | CGAAATGCAC | CCCGCATTAC | GTTTGGTGGA | CCCTCAGATT | CAACTGGCAG | TAACCAGAAT |
| GGAGAACGCA | GTGGGGCGCG | ATCAAAACAA | CGTCGGCCCC | AAGGTTTACC | CAATAATACT | GCGTCTTGGT |
| TCACCGCTCT (| CAC CTTTCGGCA | AG ACGTGGTCC | A GAACAAACCO | C AAGGAAATTT | TGGGGACCAG | GAACTAATCA |
| GACAAGGAAC | TGATTACAAA | CATTGGCCGC | AAATTGCACA | ATTTGCCCCC | AGCGCTTCAG | CGTTCTTCGG |
| AATGTCGCGC | ATGGGACTTC | AGCATGGCGG | TGTTTGCAGA | TTTGGACCTG | CGAGCGGGTT | CTGACCTGAA |
| GGCTCTGCGC | GGACTTGTGG | AGACAGCCGC | TCACCTTGGC | TATTCAGTTG | TTGCTATCAA | TCATATCGTT |
| GACTTTAAGG | AAAAGAAACA | GGAAATTGAA | AAACCAGTAG | CTGTTTCTGA | ACTCTTCACA | ACTTTGCCAA |
| TTGTACAGGG | AAAATCAAGA | CCAATTAAAA | TTTTAACTAG | ATTAACAATT | ATTGTCTCGG | ATCCATCTCA |
| CTGCAATGTT | CTA GCA TAA | CCC CTT GGG | GCC TCT AAA | CGG GTC TTG | AGG GGT TTT | TTG -3' |

Figure S1: SARS-CoV-2 detection module (SDM) is flanked by T7 promoter and T7 terminator at 5' and 3', respectively, for *in vitro* transcription. Both T7 promoter and T7 terminator are italised bolded in blue. The Q β hairpin is underlined in orange, SARS-CoV-2 N1 region is in red, SARS-CoV-2 N2 region in green and RP region in black. The SDM flanked with T7 promoter and T7 terminator (SDM + T7_{P/T}) was cloned not in frame with open reading frame of plasmid to avoid proper protein translation of truncated SARS-CoV-2 gene.



Figure S2: Vector maps of plasmids for production of Q β 1P-C19 VLPs and Q β 2P-C19 VLPs. (Left) One-plasmid system for production of Q β 1P-C19 VLPs: SDM + T7_{P/T} was cloned downstream of Q β capsid protein in plasmid pCDFDuetTM-Q β to construct plasmid Q β 1P-C19. (**Right**) Two-plasmid system for production of Q β 2-C19 VLPs: SDM + T7_{P/T} was cloned in pET-28a (+) to construct plasmid Q β 2P-C19 and co-express Q β capsid protein from pCDFDuetTM-Q β . N1, N2, and RP in SDM were indicated as red, green, and black, respectively.



Figure S3: Characterization of the *in vitro* transcribed SDM RNA. (A) Analysis of *in vitro* transcribed SDM RNA on a denaturing 6% urea polyacrylamide gel. M: Thermo Fisher Scientific CenturyTM-Plus RNA Markers. Lane 1: 200 ngvof SDM RNA. (B) Determination of purity of SDM RNA by Nanodrop. Ratio 260/280 and 260#230 Were determined. (C) RT-qPCR of *in vitro* transcribed SDM RNA (COVID +) by US CDC primers/probes sets for all the three regions (N1, N2, RP). No template control (NTC) serves as negative control.



Figure S4: Characterization of Qβ VLP by DLS, SEC, and TEM.



Figure S5: Characterization of wild type (WT) CCMV by DLS, SEC, and TEM. Disassembled CCMV was analysed by agarose gel shown at right bottom panel. Lane 1: WT CCMV. Lane 2: Disassembled CCMV. The same gel was stained by GelRed and Coomassie blue to show the presence/absence of RNA.



Figure S6: (A) Total nucleic acids extracted from VLPs were analysed on 6 % denaturing urea polyacrylamide gel. M: Thermo Fisher Scientific CenturyTM-Plus RNA Markers. Lane 1: Q β VLP. Lane 2: Q β 1P-C19. Lane 3: Q β 2P-C19. Lane 4: CCMV-C19. Arrow indicates the SDM RNA. A total of 150 ng RNA was loaded into each well. (B) Equations for normalisation of copy number.

Table S1. Stability study: Analysis of RNAs from one-month old VLP-based SARS-CoV-2 positive controls. Total nucleic acids include carrier RNA.

| | Qβ 1P-C19 | Qβ 2P-C19 | CCMV-C19 |
|---------------------------------|-----------|-----------|----------|
| Total nucleic acids (ng/µg VLP) | 223 | 169 | 106 |
| 260/280 | 2.58 | 2.54 | 2.89 |
| 260/230 | 2.74 | 5.56 | 3.19 |

Table S2. Sequences of ddPCR primers and probes used in clinical settings.

| Primer/probe | Sequence (5'- 3') |
|--------------|--|
| N1-F | GAC CCC AAA ATC AGC GAA AT |
| N1-R | TCT GGT TAC TGC CAG TTG AAT CTG |
| N1-P | FAM/ZEN - ACC CCG CAT TAC GTT TGG TGG ACC - IBFQ |
| N2-F | TTA CAA ACA TTG GCC GCA AA |
| N2-R | GCG CGA CAT TCC GAA GAA |
| N2-P | FAM/ZEN - ACA ATT TGC CCC CAG CGC TTC AG - IBFQ |
| RP-F | GATTTGGACCTGCGAGCG |
| RP-R | GCGGCTGTCTCCACAAGT |
| RP-P | HEX/ZEN - CTGACCTGAAGGCTCT- IBFQ |

*F refers to forward; R refers to reverse; P refers to probe

| | Qβ 1P-C19 | Qβ 2P-C19 | CCMV-C19 |
|--------------------------------|-------------------------|-------------------------|-------------------------|
| Protein concentration | 2.60 x 10 ⁻⁵ | 2.94 x 10 ⁻⁴ | 2.66 x 10 ⁻⁵ |
| (µg*mol/g*mL) | | | |
| Total RNA concentration | 7.42 | 51.63 | 16.71 |
| (μg/mL) | | | |
| Percentage of SDM RNA in | 3.98 | 3.80 | 100 |
| total RNA (%) | | | |
| SDM RNA concentration | 1.48 x 10 ⁻⁶ | 9.86 x 10 ⁻⁶ | 8.40 x 10 ⁻⁵ |
| (µg*mol/g*mL) | | | |
| Number of SDM RNA/particle | 0.06 | 0.03 | 3.15 |

 Table S3. Calculation of SDM RNA molecule encapsidated in VLPs.